Qiagen Stock Price, News & Analysis

QIAGEN (NYSE: QGEN) has announced a partnership with Bode Technology, making Bode the exclusive global commercial partner for the GEDmatch PRO genealogy database. This database assists police and forensic teams with investigative comparisons of genetic data. The multi-year agreement aims to accelerate the use of GEDmatch PRO in law enforcement and identification of human remains.

Key points of the partnership include:

• Bode will manage all commercial transactions for GEDmatch PRO globally
• QIAGEN will continue developing new features with input from Bode's genealogy experts
• The partnership leverages QIAGEN's expertise in forensic products and Bode's forensic services
• It will boost the use of QIAGEN's next-generation sequencing (NGS) products in human identification and forensic investigations

This collaboration is expected to enhance the adoption of extensive DNA data in solving cold cases and bring resolution to victims' families and friends.

QIAGEN (NYSE: QGEN) has expanded its QIAcuity digital PCR platform with over 100 new assays for cancer research, genetic disorders, and infectious disease surveillance. The company has launched more than 130 new assays in 2024, surpassing its goal and bringing the total to over 2,300 validated assays.

Key developments include:

• New dPCR LNA Mutation and CNV Probe Assays for cancer-relevant mutations
• dPCR Microbial DNA Detection Assays for pathogens and antibiotic resistance
• Expanded portfolio for animal diseases and plant pathogens

QIAcuity has seen strong adoption with over 2,000 placements by end of 2023. An in-vitro diagnostic version is set for launch in fall 2024, targeting clinical applications. QIAGEN is also partnering with pharma companies to develop companion diagnostics on the platform.

QIAGEN (NYSE: QGEN) has expanded its strategic partnership with Bio-Manguinhos/Fiocruz, Brazil's leading provider of vaccines and diagnostics. The collaboration enhances Brazil's national blood screening program with advanced PCR-based molecular testing for malaria, HIV, hepatitis B, and C. Additionally, it supports epidemiological surveillance of Brazil's ongoing dengue outbreak.

The new NAT Plus platform, utilizing QIAGEN's PCR reagents, is now operational in 30 laboratories across Brazil, processing 3.5 million samples annually. This advancement significantly improves transfusional safety by detecting malaria and reducing the diagnostic window for infections. QIAGEN will provide critical molecular biology technologies, custom solutions, and comprehensive training to support this public health initiative.

QIAGEN (NYSE: QGEN) has announced a collaboration with Eli Lilly to develop a QIAstat-Dx in-vitro diagnostic (IVD) panel for APOE genotyping, which can aid in the diagnosis of Alzheimer's disease. This marks the first commercially available IVD for APOE genotyping and expands QIAstat-Dx's applications into neurodegenerative diseases.

The QIAstat-Dx system, with over 4,000 instruments worldwide, uses single-use cartridges and multiplex real-time PCR to detect genetic variants in about an hour. The new panel will detect all APOE genotypes (APOE2, APOE3, APOE4), with APOE4 carriers having a higher risk of developing Alzheimer's earlier in life.

This collaboration adds to QIAGEN's portfolio of over 30 master agreements with pharmaceutical and biotech companies for diagnostic test development across various technologies and disease areas.

QIAGEN has expanded its partnership with AstraZeneca to develop and commercialize companion diagnostics (CDx) for chronic diseases using the QIAstat-Dx platform. This agreement extends their collaboration beyond oncology, enabling fast decision-making for patient suitability for AstraZeneca's genomically targeted medicines. QIAGEN will develop a genotyping assay for the QIAstat-Dx system, which can provide results in about an hour using multiplex real-time PCR technology.

The QIAstat-Dx platform, with over 4,000 cumulative instrument placements by the end of 2023, offers cost-efficient, single-use cartridges and provides additional insights through cycle threshold values and amplification curves. This expansion showcases QIAGEN's expertise in CDx development and its ability to tailor products to partners' needs across various technologies, including PCR, digital PCR, and next-generation sequencing.

QIAGEN reported solid Q2 2024 performance, exceeding its outlook. Net sales reached $496 million, stable year-over-year but up 1% at constant exchange rates (CER). Adjusted diluted EPS was $0.55, surpassing the $0.52 CER outlook. The adjusted operating income margin improved to 28.4%, up from 27.4% in Q2 2023. Free cash flow increased 56% to $129 million.

Based on strong H1 2024 results, QIAGEN updated its FY 2024 outlook. The company now expects net sales of at least $1.985 billion CER, reflecting solid core business trends and the decision to phase out the NeuMoDx system. The adjusted diluted EPS outlook was raised to at least $2.16 CER, with an adjusted operating income margin target of at least 28.5%.

QIAGEN announced a partnership with the University of Montana's Snow Molecular Anthropology Lab to advance forensic services for identifying remains of missing and murdered Indigenous people (MMIP) and unidentified human remains (UHRs). The collaboration involves using DNA technologies, including next-generation sequencing (NGS) and forensic investigative genetic genealogy (FIGG). QIAGEN will provide the lab with MiSeq FGx sequencing systems, ForenSeq Kintelligence kits, and training. The partnership aims to build the first Indigenous-owned DNA database and identify the remains of 95 African American individuals discovered in Sugar Land, Texas. The collaboration underscores QIAGEN’s leadership in forensic applications, focusing on delivering accurate results and culturally sensitive practices. The initiative will also help families affected by the MMIP epidemic, using modern technologies to trace loved ones' identities while respecting cultural practices.

QIAGEN N.V. (NYSE: QGEN) will release its Q2 2024 financial results on July 31, 2024, just after 22:05 Frankfurt time, 21:05 London time, and 16:05 New York time. The company will hold a conference call discussing the results on August 1, 2024, at 15:00 Frankfurt time, 14:00 London time, and 09:00 New York time. Participants can join via a call-back service, dial-in by phone, or access an audio webcast. Registration for call-back and webcast access is available 15 minutes before the call starts. A replay of the conference call will be accessible via a web link.

QIAGEN announced the endorsement of its QuantiFERON-TB Gold Plus test by the American Academy of Pediatrics (AAP) for detecting latent tuberculosis (TB) in children of all ages. The AAP's new guidelines recommend using modern blood-based tests, such as IGRA, to screen at-risk children, emphasizing their accuracy and efficiency over traditional skin tests. This adjustment aligns with broader U.S. trends shifting towards improved TB control methods, especially important given the recent 16% increase in active TB cases in the U.S. The updated guidelines are expected to enhance early detection and treatment, preventing the progression to active TB disease.